All Activity

“Hemp beverages deserve the same kind of framework alcoholic beverages do. What I don’t believe is that the only two choices are an unregulated market or eliminating these products as a whole.” By Micah Hyde, Former NFL Player Alcohol has been around through many stages of my life. It’s been there at celebrations, dinners, countless nights out, college parties, game days, wins and losses. Like many, I drank socially, but one thing always remained true: I hated the way it made me feel, especially the morning after. I spent 12 years in the National Football League (NFL), and as my career went on, that tradeoff made less and less sense. After a game, my body and mind had already been through enough. I was sore, tired and focused on recovering so I could do it all over again days later. It was depleting mentally, physically and emotionally. Adding a night of drinking only to feel even worse the next morning never appealed to me, and it was never worth it. Toward the end of my career, I started looking for another option and eventually found low-dose hemp products. I could relax, enjoy a buzz with my friends and still wake up feeling like myself the next day, ready to perform. The problem was that I still wanted the experience of cracking open an ice cold beer, and that is where the idea of Hyde’s Hail Mary was born. I wanted to create something that felt familiar, something I could have while watching a game, sitting around with friends or unwinding after a long day, without alcohol. Federal rules don’t allow THC to simply be added to beer, so I had to work with formulators to develop a malt-forward shandy that could deliver that same kind of experience in a completely different and better way. I retired from the NFL in 2025 (Go Bills) and launched Hyde’s Hail Mary that August. My name may be on the can, but I am not just the face of the company. Building this brand has meant learning every part of the business, which I can honestly say I’ve enjoyed. From the formulation, lab testing and compliance to the QR codes printed on every can, I’m learning it all. I spent my football career obsessing over details because every detail mattered, and I’ve brought that same mentality into my business. In fact, I can no longer look at a can sitting on a table without thinking about all that went into getting it there. Today, Hail Mary has four flavors on shelves in Louisiana, Texas, Illinois, Wisconsin and New York. Our Apple Shandy, a flavor my wife developed, won a silver award at the LA Spirits Awards in our very first year. During home games, you can find our team outside of Highmark Stadium amongst the best fans in the world, handing out samples in a city that means everything to me and my family. One of the biggest surprises has been understanding who our customers really are. When we launched, I assumed we’d be targeting people in their twenties. To my surprise, a large part of our customer base stands between 35 and 55. Many are parents, and men and women buy the product at nearly the same rate. They are not necessarily looking to party, though maybe some are. A lot of them are looking for the same thing I was: a way to unwind and enjoy something at the end of the day while still feeling good the next morning, and they keep coming back. That is why what’s happening in Washington, D.C. matters beyond belief. Unless Congress acts, a new federal definition of hemp is scheduled to take effect on December 11. Among other changes, hemp-derived cannabinoids containing more than 0.4 milligrams of total THC per container will no longer fall within the federal definition of hemp. For beverages like Hyde’s Hail Mary, a product I take so much pride in, that would eliminate the product entirely. The uncertainty is already affecting small businesses like mine. Two distribution opportunities we spent months developing fell apart this year because distributors simply don’t know how this is going to play out. I don’t blame them, but it is absolutely unfortunate. That uncertainty affects every decision we make, and matter of fact, it affects everything. Beverages have expiration dates, and we can’t manufacture unlimited inventory and leave it sitting in a warehouse while we wait for Washington to decide whether we will legally be able to sell. Our best-selling flavor is nearly sold out, and right now I have to think carefully about how much more we can produce. I understand why lawmakers want rules and regulations around this industry, and I want rules, too. I believe hemp beverages should be regulated and sold only to adults 21 and over. Products should be independently tested and clearly labeled and they should be produced and sold by companies willing to follow real standards with integrity. I would happily support reasonable limits on the amount of THC permitted in a beverage, including a 10 milligram per container cap. We already sell through licensed dispensaries in New York, and I have seen firsthand that a regulated system with testing, age checks and real oversight works. Hemp beverages deserve the same kind of framework alcoholic beverages do. What I don’t believe is that the only two choices are an unregulated market or eliminating these products as a whole. There is a responsible middle ground. Adults should be able to choose a properly tested and clearly labeled low-dose hemp beverage just as they would an alcoholic one. These drinks have changed the way I experience the game I spent most of my life playing. I can go to a game, have something in hand, enjoy the atmosphere and stay completely present for the one thing I came to see: football. I can watch plays develop and enjoy the game without feeling like alcohol has to be a part of the experience, and I know plenty of people who want the same. For me, Hail Mary started with a pretty simple question about why there wasn’t something better for people who wanted to unwind without alcohol, so I built it. To every reader who enjoys hemp beverages, I invite you to visit the Hemp Beverage Alliance action center to tell Congress in a single sentence why you support safe, regulated sales. What Congress does next will determine whether businesses like Hyde’s Hail Mary get the chance to keep going. Micah Hyde, the founder of Hyde’s Hail Mary, is a former National Football League Player. The post Congress Should Regulate Hemp THC Drinks Like Alcohol Instead Of Banning Them, Former NFL Player Says (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

South Dakota’s attorney general says the Trump administration’s move to reschedule medical marijuana will have little effect on the state’s medical cannabis program, concluding that federal rules provide a pathway for state-licensed businesses to continue operating with the necessary registrations. The opinion, published on Tuesday by Attorney General Marty Jackley (R), comes as officials in states across the U.S. work to understand the implications of the major shift in federal marijuana policy—and after some South Dakota lawmakers sought to repeal the state’s medical cannabis program in light of federal rescheduling. “Because current Drug Enforcement Administration (DEA) administrative rules permit state medical-marijuana facilities to continue operating with proper federal and state registration, the federal rescheduling of marijuana will likely have a negligible impact on South Dakota’s medical-marijuana program,” the attorney general wrote. “The federal rescheduling of marijuana does not preempt South Dakota’s medical-marijuana program because Congress has not expressly preempted state action, it has not totally occupied the field of marijuana regulation, and South Dakota’s medical-marijuana law does not conflict with the federal scheduling,” he said. “In fact, under DEA’s April 2026 rule, an existing manufacturer, distributor, or dispensary operating under a valid state license may now do so in compliance with federal law if they register with the DEA.” Under an order issued by Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An administrative hearing is considering broader marijuana rescheduling. Jackley’s new opinion, which was requested by lawmakers who serve on the legislature’s Medical Marijuana Oversight Committee, said the state has “faced a somewhat analogous situation previously” with respect to federal hemp legalization. It pointed out that a court agreed that police powers are traditionally reserved to states and that a “no preemption” clause in the federal legislation that legalized hemp eliminated any potential for preemption. “Similarly, federal rules currently permit actors in the state medical-marijuana industry to continue to function so long as they obtain the proper federal and state credentials,” the South Dakota attorney general wrote. “Because federal law accommodates the state’s medical-marijuana program, state law does not conflict with dispensing of Schedule III marijuana or cannabinoid medication under federal law.” @SDAttorneyGen Marty Jackley: At the request of a state Senator, I have issued an official opinion stating that the federal rescheduling of marijuana as a Schedule III controlled substance will NOT impact South Dakota’s Medical Marijuana program.https://t.co/g5g1zBs0J1 pic.twitter.com/nJxU0RYZxo — SD Attorney General Marty Jackley (@SDAttorneyGen) October 13, 2026 South Dakota doesn’t currently schedule marijuana as a controlled substance under state law, though it does criminalize possession and distribution outside of the medical cannabis program. “If South Dakota were to choose to reschedule marijuana to a Schedule III controlled substance, then the general rules regarding Schedule III substances would apply to marijuana as with any other Schedule III substance,” Jackley said. “But this action would have to be taken by either the Legislature or the voters, independent from the rescheduling of marijuana federally.” Lawmakers had laid out six potential options of future state cannabis policy actions in their request to the attorney general, and he replied that “none of them would be excluded by current federal or state law” but that it would be up to the legislature and voters to decide which, if any, to pursue. “Changes to marijuana’s scheduling by the federal government were accompanied by an explicit pathway through which participants in state medical-marijuana programs may be registered with the federal government and continue to operate,” Jackley said. “Because federal law explicitly permits state medical-marijuana programs, South Dakota’s program may continue to operate as it has without impact from marijuana’s federal rescheduling to a Schedule III controlled substance. The attorney general’s opinion comes after South Dakota lawmakers weighed legislation this session on federal rescheduling’s impact—including one bill that would have repealed the state’s medical marijuana law 90 days after the attorney general certified that cannabis had been federally rescheduled to Schedule III. Meanwhile, South Dakota regulators have voiced uncertainty about how federal marijuana rescheduling will work in conjunction with the state’s law. State medical cannabis program administrator Whitney Brunner told lawmakers in August that officials had received little federal guidance beyond requests for information. The post Federal Marijuana Rescheduling Will Have ‘Negligible Impact’ On South Dakota’s Medical Cannabis Program, Attorney General Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Long-held anti-marijuana attitudes in sports leagues are “evolving” as social trends are “driving more openness to cannabis” as an alternative to opioids for treating athletes’ pain—but ongoing stigma creates trust issues that makes it harder for medical staff to do their jobs, according to a new study funded by the National Football League (NFL). “Negative perceptions and longstanding stigma continue to shape how cannabis use is viewed among athletes, medical staff, and society, making open discussion difficult,” the study, published this week in the journal Sports Health, said. However, “medical professionals, particularly younger or research-focused staff, are increasingly seeing cannabis as a safer or more effective option than alcohol, opioids, or other prescription drugs.” The qualitative research, which was partially funded by the joint pain management committee overseen by the NFL and the NFL Players Association, involved interviews with 10 medical staff from professional and collegiate leagues. That includes the NFL as well as the National Basketball Association (NBA), Major League Baseball (MLB), National Hockey League (NHL), National Collegiate Athletic Association (NCAA) and others. Interviewees largely said they feel “unqualified” to assist athletes on cannabis issues due to “limited education and experience,” the researchers at the University of Saskatchewan and University of Regina in Canada wrote. “Targeted cannabinoid education, destigmatization, and clearer league policies are essential to optimize athlete care and harm reduction as cannabis use grows in elite sport.” Athletic medical professionals also reported “ongoing confusion and anxiety about legal status, league policies, and compliance requirements related to cannabinoids” which “discourage open communication and appropriate athlete support.” Due to uncertainty about the rapidly changing legal and policy landscape on the issue, “many staff avoid advising on cannabis altogether,” the study said. Meanwhile, the researchers noted that “alcohol remains widely accepted and normalized in sports culture, in contrast with the strict controls on cannabis.” “Many recognize that, despite health risks, alcohol is encouraged while cannabis remains taboo.” Decades of anti-drug campaigns and institutional messages has left many athletes and staff in fear being “judged, punished, or jeopardizing their positions in sport” over marijuana—and drug testing for cannabis “adds to the stigma,” the study said. While cannabis remains “largely taboo” in sports, social trends and the growing legalization movement has played a role in reducing the stigma—”with younger and research-oriented medical staff adopting more open, health-centered perspectives,” the researchers noted. “Shifts in cannabis laws have fostered openness and curiosity. Legalization encourages staff and athletes to discuss cannabis use more freely and increases inquiries, as staff feel more able to address the topic,” they said. “Direct exposure to cannabis, seeing its effects on patients, and changes in legal status are leading to gradually more positive perceptions.” More athletes are gravitating toward cannabis for both recreational and medical use in recent years, the study noted. “Athletes prefer cannabis for perceived benefits over alcohol, such as fewer negative side effects and less disruption to training,” it said. “Medical staff report athletes seek cannabis to manage pain, inflammation, anxiety, and sleep problems.” “Athletes are increasingly initiating discussions with staff about cannabis, focusing on its therapeutic effects and compliance with league rules.” Athletic physicians, trainers, nutritionists and mental health professionals are also opening up to the benefits of marijuana as an alternative medical treatment. “Medical staff increasingly perceive cannabis as safer than opioids or certain prescription drugs, especially in sports,” the researchers said. “Long-term medication risks, including opioid addiction, have made staff more open to alternatives.” The researchers highlighted a number of specific comments made during their interviews with athletic medical staff: “Every team is sponsored by alcohol, yet as soon as you mention cannabis it’s a big no, no.” “I would think it [cannabis] is safer, I would 100% think it’s safer [than opioids]. Again, not because I have enough knowledge of cannabis, but I have enough knowledge of the dangers of opioids.” “The education that I’ve received on it [cannabis] has been pretty much nothing, so anything helping to educate myself and the performance department on it would be beneficial.” “I have my master’s degree, and we didn’t touch it [cannabis education]. Never talked about it.” “I think if there is a course that is provided, I would definitely love to sign up for that, just to get more knowledge.” “They are so petrified to even mention it [cannabis] to their doctor because they’re worried about the ramifications.” “I think the guys have a tough time talking to me about it [cannabis], because they’re not really sure what or how I’m gonna react.” “There’s been some pretty positive benefits [from using cannabinoids], and…it’s been something that has helped them” “It [cannabis] is, I would say, not openly discussed, still pretty taboo.” “There’s some hesitation or fear because I’m contracted through the organization that they don’t know where that information is going.” In conclusion, the researchers said the findings of the study “identify a considerable lack of knowledge about cannabis use by medical personnel working with athletes in elite level sports and underscore the pressing need for targeted education and policy alignment.” The paper noted that major sports leagues have changed their policies in recent years to remove strict punishments for cannabis use. Most recently, for example, the Women’s National Basketball Association (WNBA) this year removed marijuana from its prohibited substances list while also laying out rules for how players can invest in and promote cannabis companies. A previous NFL-funded study by the same research team focused on athletes’ views on cannabis in sports, finding that many feel they aren’t getting adequate information about cannabis from their teams’ and leagues’ health officials due to ongoing stigma around the issue. “Elite contact sport athletes use cannabis intentionally for recreational, therapeutic, and recovery purposes but face systemic barriers related to misinformation, stigma, and inconsistent policy guidance,” that study said. “As cannabis legality expands, this potential knowledge gap impairs athletes’ ability to make informed decisions about cannabis for health and performance. Lack of knowledge increases exposure to unregulated products, and may cause athletes to overlook potential therapeutic benefits.” The researchers behind the new study also previously published a study in 2024 that highlighted the growing acceptability of medical cannabis in sports, while also underscoring the obstacles to marijuana research caused by ongoing federal prohibition. NFL and the league’s players union in recent years have put a focus on funding research related to cannabis and athletes. In 2022, for example, they authorized $1 million in grants for a pair of studies looking into the efficacy of marijuana and its components in managing football players’ pain and providing neuroprotection from concussions. The league and the players union also awarded funding to support research on the therapeutic benefits of CBD as a pain treatment alternative to opioids for players with concussions. The NFL reached an agreement with its players union in 2024 to further reform its marijuana policies, significantly reducing fines for positive tests while increasing the allowable THC threshold for players. About four years after NFL ended the practice of suspending players over cannabis or other drugs as part of a collective bargaining agreement, the league again revised its Substances of Abuse Policy and Performance Enhancing Substances Policy. NBA, for its part, removed marijuana from the banned substances list for players in 2023, and it also freed them up to invest in and promote cannabis companies. The National Collegiate Athletic Association (NCAA) in 2024 voted to remove marijuana from its banned substances list for Division I players. The reform builds on a 2022 change that increased the allowable THC threshold for college athletes, aligning NCAA’s rules with those of the World Anti-Doping Agency (WADA). The head of the U.S. Anti-Doping Agency (USADA) blasted the “unfair” ban on marijuana for athletes competing in international sport events, including the Olympics that were underway in Paris at the time of the comments. USADA CEO Travis Tygart said it was “disappointing” that WADA has maintained the cannabis prohibition based on what he considers a misguided justification. WADA did carry out a review into its marijuana policy at the request of USADA and the White House Office of National Drug Control Policy (ONDCP) following the controversial suspension of U.S. runner Sha’Carri Richardson, who was barred from participating in the Olympics in 2021 after she tested positive for THC. Richardson said she used cannabis to cope with the recent passing of her mother. While UFC announced in late 2023 that it was formally removing marijuana from its modified banned substances list for athletes, the league notified participants that the reform didn’t apply under California State Athletic Commission (CSAC) rules. UFC advised fighters that they could be subject to a $100 fine by CSAS if they tested over 150 nanograms of THC per milliliter ahead of the UFC 298 event that took place in February. Image element courtesy of Marco Verch. The post Anti-Marijuana Attitudes In Sports Are Easing Up, But Ongoing Stigma Makes Athletic Trainers’ Jobs Harder, NFL-Funded Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Idaho lawmakers know that they can no longer make a rational case for the state’s prohibitive and punitive marijuana policies.” By Paul Armentano, NORML Regardless of one’s views on marijuana, Idahoans must reject HJR 4 this November. House Joint Resolution 4 seeks to amend the state constitution so that voters no longer have any say in determining Idaho’s drug policies. That’s not anti-marijuana, that’s anti-democracy. HJR 4 mandates, “Only the legislature of the state of Idaho shall have power and authority to legalize…marijuana or other psychoactive substances.” The message behind this resolution cannot be clearer. State officials don’t trust voters to do their bidding on the marijuana issue. Lawmakers’ apprehensions are well deserved. They understand that their “reefer madness” views are out of step with most Idahoans. For example, nearly 70 percent of Idahoans said in a poll that “the use of marijuana for medical purposes should be made legal.” Yet, despite this popular support, most lawmakers would rather stick their collective heads in the sand. That is why they are seeking to remove voters from the equation permanently. For decades, voters have been far ahead of their elected officials on matters pertaining to the legalization of marijuana for medical and adult-use purposes. Many of the 41 states with legal medical cannabis access did so by voter initiative. Ditto the 24 states where marijuana is legal for adults. In short, politicians dragged their feet and voters took matters into their own hands. Those voters don’t regret their decisions. No state has ever repealed its marijuana legalization laws. In fact, public support for legalization is greater today than at nearly any time in our nation’s history. This reality has Idaho lawmakers, and Republicans especially, running scared. They know that their antiquated views on cannabis are unpopular with voters. But rather than evolve their views to align with those of their constituents, they’d rather eliminate voters from the democratic process altogether In a healthy democracy, those with competing visions on public policy vie for voters’ support. They seek to persuade and influence the electorate by making sound arguments and by providing hard evidence. But Idaho lawmakers know that they can no longer make a rational case for the state’s prohibitive and punitive marijuana policies—policies that are out-of-step not only with most other states, but also with most Idahoans. As a result, they are asking Idahoans to relinquish one of the most fundamental powers they have in a free society: their power to vote. Whether or not one personally supports or opposes cannabis legalization, these undemocratic tactics ought to cause Idahoans—and, quite frankly, all voters—deep concern. Paul Armentano is the Deputy Director for NORML, the National Organization for the Reform of Marijuana Laws. The post Idaho Ballot Measure To Block Voters From Legalizing Marijuana Is Anti-Democracy (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I haven’t any word to appreciate this post.....Really i am impressed from this post....the person who create this post it was a great human..thanks for shared this with us. dewalive

It’s time to for Kansas to legalize marijuana and stop letting other states collect tax revenue by selling cannabis to its residents, the Democratic Party’s nominee for governor in next month’s election says. She is also calling out her Republican opponent for blocking marijuana reform bills in the legislature despite public support. “I believe close to 70 percent of the population is in favor of legalization, but you get a few people once in a while who will say, ‘Well, we don’t want to bring that here,'” Cindy Holscher, who currently serves as a state senator, said in an interview with 12 News. “My response: It’s already here. If you drive along state line in Johnson County, you drive along the border on the southern edge to Oklahoma, and you see the dispensaries—there’s Kansas plates there,” she said. “So it’s already here.” “But what’s happening is we aren’t getting the revenue for it, and we aren’t getting our guardrails in place. We need to do that,” Holscher said. “The revenue that’s projected to come in could help us do things like better funding public education in terms of special ed, could help us in terms of free lunches for kids—making that part of the day. You know there are things that we could do with that money to help build up our critical infrastructure and be better focused on our people.” The Democratic gubernatorial candidate also spoke about marijuana legalization in another interview with The University Daily Kansan, saying that the “good news, or silver lining, in terms of being one of the last states is that we can take the good models that are out there to replicate here.” “And we’ve seen things that don’t work, so we’re in a position to adopt the best situation possible,” she said. Holscher additionally discussed the fiscal impact of cannabis legalization in a separate interview with KMBC 9. “I will tell you I’m a supporter of legalizing cannabis, as well as the bulk of the population of Kansans,” she said. “Anywhere from 65 to 75 percent of Kansans support legalization. That in Missouri has amounted to $255 million in revenue.” Asked how she would get cannabis reform through a Republican-controlled legislature, Holscher said she and allies succeeded in passing a medical cannabis bill through the state House of Representatives in 2021 that went on to die in the Senate—putting blame for the ultimate defeat on her opponent in the governor’s race, Kansas Senate President Ty Masterson (R). “You know, I got it passed in the House a few years ago. Guess who stopped it in the Senate? Ty Masterson,” she said. “The things that people want, the things that people support, he has been stopping.” Later in the interview, Holscher was pressed on how she would succeed in garnering the support of moderate voters while her political opponents tag her as a “radical.” “The things I’m fighting for—Medicaid expansion, legalizing cannabis, funding of our schools, lowering property taxes—those are all things that are supported by anywhere from 65 to 75 percent of the Kansas population, she said. “I’m not extreme. I’m mainstream. You know what’s extreme? The fact that my opponent is pushing back against the things that Kansans overwhelmingly support. Time and time again, Ty Masterson has pushed back against Medicaid expansion, legalizing of cannabis.” Masterson, for his part, said in 2023 that was open to a discussion about a limited medical marijuana program. But in 2024, he appeared less welcoming to the idea, calling medical cannabis legalization a “nonstarter,” suggesting the policy change would lead to a surge in “gang activity” and put kids at risk. Incumbent Kansas Gov. Laura Kelly (D) said last year that it’s time for lawmakers in the state to finally legalize medical marijuana. Polling from last year found that 70 percent of Kansans support legalizing medical marijuana. About six in 10 (59 percent) of respondents also said they supported more broadly legalizing recreational cannabis. After the House of Representatives passed a medical cannabis bill in 2021, it stalled out in the Senate. And while the Senate Federal and State Affairs Committee held numerous hearings on the issue, it voted in 2024 to table a limited medical marijuana pilot program bill. A later effort to revive the medical cannabis bill on the Senate floor ultimately fell short. That measure was filed about a month after the House rejected a Democratic lawmaker’s amendment to a broader drug scheduling bill that would have removed marijuana entirely from the state’s controlled substances law, effectively legalizing it. In 2024, meanwhile, a state legislative panel voted against a proposed recommendation that lawmakers legalize medical cannabis in 2025. The legislature’s Special Committee on Medical Marijuana, charged with consideration of possible pathways for medical cannabis reform, said legalizing medical marijuana was premature and that lawmakers should first wait to see how federal rescheduling and other reform efforts unfold. The post Kansas Should Legalize Marijuana, Democratic Candidate For Governor Says, Criticizing GOP Opponent For Blocking Medical Access appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Superior Place, My organization is a great believer during ad opinions regarding online websites that will let the webpage novelists recognize that they’ve put in an item worthwhile that will the online market place! Lucerne Grand Showflat

Cyberspace is without a doubt bogged downward through fake blogging and no realistic note nevertheless blog post is fabulous and even worthy that browse. Thanks for your time designed for writing it with me at night. Lentor Heights Showflat

I high appreciate this post. It’s hard to find the good from the bad sometimes, but I think you’ve nailed it! would you mind updating your blog with more information? 7meter

WI gov candidate: Legalize marijuana; WA officials invite cannabis comments; Study: Medical marijuana for cancer symptoms; NC hemp industry Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… *Rattling the tip jar* Got a few dollars you can spare to help Marijuana Moment pay our writers, keep our website running and grow into the kind of robust news organization the fast-paced world of drug policy deserves? Join us for $25/month and be a part of our work: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Wisconsin Democratic gubernatorial candidate David Crowley said the state should legalize marijuana to raise revenue that can be used to fund free pre-K and expanded healthcare access. The Washington State Liquor and Cannabis Board is accepting public comments on a proposal to create a process allowing marijuana businesses to document their participation in the medical cannabis market in order to ease their access to benefits under federal rescheduling. A new federally funded study found that “most cannabis users reported that it improved their cancer-related symptoms”—including pain, appetite, mood and insomnia—while also serving as a substitute for opioids for nearly a third of them. “Symptom improvement was reported for insomnia (89.7% of users), appetite (85.7%), mood (83.7%), joint pains/stiffness (83.3%), stress/anxiety/depression (81.6%), cancer-related pain (80.7%) and digestive symptoms (67.9%).” Dentons’s Eric P. Berlin and Joanne Caceres argue in a new Marijuana Moment op-ed that while the timeline for an ongoing cannabis rescheduling hearing has “slipped” as opponents seek to insert a critical report into the record, “this is a delay, not a defeat, and the industry should not panic.” “Reports of the marijuana rescheduling proceeding’s death are greatly exaggerated… This is a procedural pause, nothing more.” North Carolina businesses are bracing for the impact of the federal recriminalization of hemp THC products that is set to take effect this year. / FEDERAL The White House Office of National Drug Control Policy published an overview of youth drug use data. / STATES Puerto Rico Gov. Jenniffer González-Colón (R) signed a bill creating exceptions to employment protections for medical cannabis patients in safety-sensitive transportation jobs. A North Carolina representative discussed her views on marijuana and hemp policy. Connecticut regulators published guidance on medical cannabis purchases by out-of-state patients. Oklahoma regulators clarified that a recent email on flavoring and coloring ingredients in medical cannabis production batches was sent in error. Missouri regulators published the latest episode of their cannabis podcast. Nevada regulators will host a cannabis public safety and consumer fair on November 4. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Canadian officials said cannabis was the country’s “fifth most important cash crop” in 2025. The Romanian General Prosecutor’s Office is opposing a bill to decriminalize drug possession. / SCIENCE & HEALTH A study found that “an estimated 23.1% of US adults reported past 12-month cannabis use: 62.6% smoked, 57.6% consumed, 40.1% vaped, 15.2% applied lotion, and 12.4% dabbed, with over half (52.7%) endorsing >1 route of administration.” A study’s findings “suggest the selective effects of cannabidiol on tumour cells and support its potential as a targeted bioactive agent.” / ADVOCACY, OPINION & ANALYSIS ASTM International issued a call for papers about hemp-lime composites for sustainable construction. The Marijuana Policy Project published a Wisconsin voter guide ahead of next month’s elections. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Cannabis rescheduling is just paused, not derailed (Newsletter: October 13, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

They bring fresh energy to every meeting. An Escort Service In Jangpura ensures you never feel rushed or ignored. Our partners focus on intimate conversation and physical chemistry that leads to pleasure. We invite you into a trustworthy world where fantasy comes alive.

“Regulation is what we need. Prohibition is just hilarious regression.” By Trevon Spencer, NC Newsline Chris Karazin started Carolindica with his brother and a friend in 2019, making homemade CBD products in a kitchen while working other jobs to pay the bills. “I didn’t even get a paycheck until three years ago,” Karazin said. Seven years later, the Raleigh-based company has grown into a multi-store hemp business with manufacturing operations and dozens of employees. New customers still walk through Carolindica’s doors every day. Now, a looming change in federal law is forcing Karazin to reconsider the company’s future. Beginning December 11, federal restrictions will sharply narrow which hemp-derived cannabinoid products qualify as legal. Congress approved the new federal regulations in 2025 as part of the tax cut and spending measure known as the One Big Beautiful Bill Act. Under the new law, the only hemp products that will be legal are those with no more than 0.4 milligrams of THC compounds per consumer container, a threshold that could outlaw many products currently sold in stores. The restrictions were originally scheduled to take effect in November, but Congress extended the deadline by a month. One part of the law is still scheduled to take effect on November 12. It excludes products that cannabis plants can’t naturally produce, including synthetic cannabinoids, from the federal definition of hemp, classifying them as marijuana. For Karazin, the impending bans on synthetic cannabinoids and THC mean he’s rethinking the products the company can continue selling, how much inventory to carry and where to invest its money. The federal restrictions follow years of rapid growth in the hemp industry, which proliferated after Congress legalized hemp production in 2018. North Carolina’s market has grown into a roughly $3 billion industry that employs about 16,000 people statewide. But North Carolina hemp businesses are now preparing for the possibility that much of that market could soon disappear. A business built around hemp The federal changes could affect more than intoxicating products such as THC gummies and drinks. CBD products, which contain small amounts of THC and other natural compounds found in hemp, could also exceed the new limit. The potential impact extends across the Triangle’s hemp retail market. A report by Raleigh Dispensaries, which maintains a database of hemp retailers in the region, found that 79 of 82 shops it tracked across seven counties listed at least one product category that would be affected by the restrictions. Jake St. Peter, the founder, said his report suggested more than 90 percent of the shops could be affected by the changes, and he’s been actively tracking how local businesses are preparing for the deadline. “I think this is really going to be a serious blow to these businesses,” he said. Some North Carolina hemp businesses are already closing as a result. Bloom Collective in Raleigh announced its closure on social media by the end of the month, saying new hemp regulations are putting “pressure on small businesses.” Other retailers and farmers began preparing for the federal restrictions last year. Owners of Durham’s Redhead Hemp said the limit could affect all of their inventory, while a Buncombe County farmer said his farm lacked the equipment to shift to THC-free products. For businesses that depend on those products, switching to a different line of merchandise isn’t straightforward. Karazin said Carolindica is exploring supplements, functional mushrooms and other products that could offer alternatives if the restrictions go through as planned. But he said many smaller hemp retailers won’t have the same options. “Most companies are retail, distribution and e-commerce,” he said. “Those types of companies have no way of adapting at all.” The restrictions would reach beyond the products sold on store shelves. Farmers growing hemp for cannabinoid products could lose buyers if manufacturers reduce production. At the same time, merchandisers could have to find new markets for products or ingredients that comply with the federal law. State lawmakers weigh additional restrictions on hemp The federal deadline is not the only regulatory challenge facing North Carolina’s hemp industry. State lawmakers have also debated legislation that would impose the same THC limit on hemp products as under the federal law, and would also ban the sale of even low-level hemp consumables, including CBD products, to people under 21. The state Senate passed the measure last summer, saying it would be a backstop in case Congress decides to revise or delay the new federal law. However, the House declined to take up the proposal during its August session under conflicting pressure from hemp businesses and law enforcement. House Speaker Destin Hall, R-Caldwell, said lawmakers needed more time to consider the issue and could reconsider it after the November elections. Meanwhile, the state’s Advisory Council on Cannabis is moving in a very different direction. The Council was created by Gov. Josh Stein (D), who is in favor of allowing a regulated cannabis market for adults only in North Carolina. The Council is developing recommendations for setting up such a market should legislators decide to allow it. Its final report is due to Stein by the end of the year. A recent poll from researchers at Elon University of over 1,000 North Carolina adults found that 75 percent of respondents were in favor of legalizing cannabis for medical use, while 55 percent were in favor of legalizing it for recreational use. Karazin said he supports regulations including age restrictions, child-resistant packaging and standardized laboratory testing. He’s worried lawmakers will eliminate the entire legal hemp market instead of creating a strong regulatory framework that could allow his business to stay open. “Regulation is what we need,” he said. “Prohibition is just hilarious regression.” This story was first published by NC Newsline. The post North Carolina’s $3 Billion Hemp Industry Braces For Impact Of Scheduled Federal THC Product Ban appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Washington State regulators are accepting public comments on a proposal to a create process allowing marijuana businesses to document their participation in the medical cannabis market in order to ease their access to benefits that come with the Trump administration’s partial rescheduling move. The Liquor and Cannabis Board (LCB) voted last week to move ahead with the plan, which is based on an advocacy group’s petition and comes after state officials said earlier this year that rescheduling cannabis on the federal level “does not appear to apply” to businesses in Washington. Under an order issued by Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). While an administrative hearing is considering broader marijuana rescheduling, Washington businesses currently have no way to verify their medical cannabis-specific activities. “Rules on this subject may be needed to consider the development and operation of a certification program for licensees participating in licensed medical cannabis activity in the state,” LCB said in an update after the vote. “This certification would serve to verify information about the regulated status of a cannabis licensee and confirm the extent of the licensee’s participation in existing state-authorized medical cannabis activities for federal registration, banking, insurance, or other lawful purposes.” While board’s vote—which came over the objection of agency staff—is a win for petitioners The Cannabis Alliance and Caitlein Ryan, it is only the beginning of potential rulemaking. “At this stage of the rulemaking process, no proposed language is offered,” LCB said in the Friday update. “Any interested party may comment on this possible rulemaking during the designated comment period.” Stakeholders can weigh in on the potential rulemaking through December 4. LCB said it “may coordinate with the Washington Department of Health and federal authorities such as the Drug Enforcement Administration to determine necessary documentation and verification of state-authorized medical cannabis activities of licensees,” though regulators in a growing number of states have complained that DEA has not been cooperative in providing guidance on complying with the federal marijuana rescheduling process. In a previously issued guidance memo in June, LCB said that “Washington does not license medical cannabis producers, processors, or retailers.” “Instead, Washington has a single recreational market and within that market producers/processors may manufacture [Department of Health]-compliant products, and certain retailers may sell DOH-compliant products to all adult patients and designated providers,” it explained. “Because of this, Washington’s cannabis licensees do not appear to qualify as ‘state medical marijuana licensee[s]’ and therefore may not be eligible to register under the Final Rule,” the agency said, referring to a Drug Enforcement Administration (DEA) registration process for state-legal marijuana businesses to take advantage of federal benefits that come with the reform. That said, LCB is “not taking a position to prevent licensees from applying for federal registration if they choose,” the guidance continued. “If any licensee does apply for federal registration, we would be interested in learning about their experience and any federal determination.” Nonetheless, “based on our analysis, federal rescheduling in its current form does not appear to apply to Washington’s cannabis licensees due to the statutory framework predominately regulating recreational cannabis,” LCB said. Washington isn’t the only state moving to reform its own marijuana rules in light of the federal rescheduling process. In California, regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent move to federally reschedule medical cannabis. Photo courtesy of Chris Wallis // Side Pocket Images. The post Washington Officials Invite Public Comments On Proposal To Make It Easier For Medical Marijuana Businesses To Access Federal Rescheduling Benefits appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Democratic Party’s nominee to be the next governor of Wisconsin says the state should legalize marijuana to raise revenue that can be used to fund free pre-kindergarten education and an expansion of healthcare access. David Crowley, who currently serves as the Milwaukee County executive, said last week that in addition to ending tax breaks for billionaires to address fiscal issues, the state should also “look at new revenues and how we grow our economy.” “We want to make sure, one, that we legalize marijuana,” he told a reporter from CBS 58 News. “That will help bring in more dollars throughout the state.” He added that he also wants to form a commission to examine fiscal issues more broadly to “permanently fix our taxing and spending problem” in the state. Meanwhile, one of David Crowley's loftiest plans is free pre-K for every 3-year-old and 4-year-old child. How will he pay for that? -Marijuana legalization -Eliminating tax breaks on the rich -A "blue ribbon commission" on all taxing and spending https://t.co/NVulyN9CR3 pic.twitter.com/g5nqMSyoDN — A.J. Bayatpour (@AJBayatpour) October 9, 2026 Crowley separately told Fox6 News that if elected his administration would need to “continue to have to work with the legislature” on solutions to fund universal pre-K and expanded access to the state’s BadgerCare program. “It’s about looking at the totality of our revenue and spending,” he said. “It’s about bringing in new revenues like the legalization of marijuana, but also making sure that the big corporations who have seen permanent tax cuts in the state of Wisconsin for the past decade and a half, that they start to pay their fair share.” The Democratic gubernatorial candidate also addressed cannabis in another interview with Wisconsin Watch, saying that “it needs to be legalized.” “We don’t have the same opportunities as folks in Minnesota and in Michigan and in Illinois,” he said. “I believe that we should support it, one, because this is a personal health position for those who want to utilize it as an alternative to a prescription drug.” “But I also look at it as an opportunity, right?” Crowley said. “Being able to grow our economy here locally, but also finding a new revenue stream to invest in things like public safety, public education and child care.” Crowley’s Republican opponent in the governor’s race, U.S. Rep. Tom Tiffany (R-W), told the outlet that he prefers to “take a go-slow approach” on marijuana “because we’ve seen some states that went straight to it, like I think about Colorado, and they had some real problems as a result of that.” “Think about Oregon, where they adopted full legalization, but then they also legalized other hard drugs. They had to pull back, and so I think those are a lesson to other states that we should take this go-slow approach,” Tiffany argued. “Also, I’ve voted federally for more money to go into research, and I think that research can inform states about what’s the best approach to take in regards to legalization.” Tiffany voted against bills to federally legalize marijuana on the House floor in 2020 and 2022, as well as an amendment in 2020 to shield state recreational cannabis laws from federal interference. He also opposed a bill to increase marijuana businesses’ access to banking services in 2021. That said, the GOP congressman’s gubernatorial campaign website says. “I support legalizing medical marijuana in Wisconsin through a responsible program that gives veterans, those suffering from chronic pain, and other patients access to the treatment they need.” “At the same time, we must have strict age requirements, responsible oversight, and strong protections to keep marijuana out of our schools and away from children,” it says. Meanwhile, a Democratic congressman who represents Wisconsin recently told Marijuana Moment that he thinks the state is poised to legalize cannabis as soon as next year—especially if his party wins control of the legislature in the November elections, but perhaps even if Republicans maintain a majority under new leadership for the 2027 session. Rep. Mark Pocan (D-WI) said there’s a “really good chance” of legalizing cannabis in Wisconsin in the short term if Democrats can “flip the legislature,” where marijuana reform proposals have stalled under Republican control in recent sessions. Pocan said, however, that he thinks cannabis legislation has a shot even if the GOP stays in control under an expected new leader in the state Assembly who is seen as more friendly to reform than the current speaker of the chamber. Gov. Tony Evers (D) and Democratic lawmakers have pushed to legalize marijuana for recreational and medical purposes for years, but those proposals have been blocked by the legislature’s Republican majority. A limited medical cannabis bill did clear one committee this session, but did not advance further. Crowley said at a forum hosted by a cannabis reform group earlier this year reform supporters “cannot wait until after the governor’s election” to push the issue, arguing that they need to “organize in making this one of the top priorities in this upcoming election.” “If you can’t change minds, you have to change faces,” he said. “I want you all to know that we’re going to work directly with you and make sure that you have a seat at the table, because if you don’t have a seat at the table, that means you’re on it.” Evers, for his part, recently sent a letter calling on the state’s congressional delegation to “prevent mass disruption of the hemp industry” by stopping the planned federal recriminalization of hemp THC products that’s set to take effect later this year. The governor has repeatedly pushed for broader reform—including marijuana legalization in multiple budget requests, for example—but efforts to enact it have consistently stalled out in the Republican-controlled Assembly and Senate even as adult-use markets have come online in neighboring states such as Illinois and Michigan. Evers said last year that if his party can take control of the legislature, the state can “finally” legalize marijuana so that residents don’t have to go to neighboring Illinois to visit its adult-use market. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Democratic lawmakers filed legislation in the 2026 session to broadly legalize and regulate marijuana, and bipartisan legislation to simply decriminalize cannabis possession was also filed—but neither proposal advanced. A poll released last year by Marquette Law School found that two in three Wisconsin voters support legalizing marijuana. A legislative analysis requested by lawmakers estimated that Wisconsin residents spent more than $121 million on cannabis in Illinois alone in 2022, contributing $36 million in tax revenue to the neighboring state. Meanwhile, the state Department of Revenue released a fiscal estimate of the economic impact of a legalization bill in 2023, projecting that the reform would generate nearly $170 million annually in tax revenue. The post Wisconsin Should Legalize Marijuana To Fund Pre-K And Healthcare Expansion, Democratic Governor Candidate Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Reports of the marijuana rescheduling proceeding’s death are greatly exaggerated… This is a procedural pause, nothing more.” By Eric P. Berlin and Joanne Caceres, Dentons Reports of the marijuana rescheduling proceeding’s death are greatly exaggerated. Despite the alarm set off by a recent Government Accountability Office (GAO) report, the Drug Enforcement Administration’s (DEA) proceeding to move cannabis from schedule I to schedule III of the Controlled Substances Act (CSA) is very much alive. The record has been in the hands of DEA Chief Administrative Law Judge (ALJ) Derek Julius since August 17, and with the midterm elections approaching, the industry expected, or at least hoped, for a rescheduling recommendation this month. That timeline has now slipped—but this is a delay, not a defeat, and the industry should not panic. This is a procedural pause, nothing more. The GAO report raised questions about process, not substance, and the stay it prompted should cost the proceeding time, not its outcome. Moreover, it has no bearing on the rescheduling of medical marijuana. Like the other substances the GAO reviewed, medical marijuana has already been formally rescheduled, and the attorney general’s medical marijuana decision rested on 21 U.S.C. § 811(d), and the United States’s international treaty obligations, with the Department of Health and Human Services (HHS) evaluation serving only as additional support. Consider the GAO report’s timing: a scheduling process that has operated unquestioned since Congress enacted the CSA in 1970—56 years ago—was suddenly found to have “gaps” only at the final stage of marijuana rescheduling. On September 23, GAO released the report. Five days later, three rescheduling opponents asked the DEA chief ALJ to add the report to the hearing record, allow more briefing and stay the proceedings. The next day, he paused the proceeding to consider their motion. Through all of this, one thing has not changed: the HHS scientific evaluation supporting schedule III. Opponents are spinning the GAO findings as a setback for rescheduling. They are not. Look at what the report and the order actually say. What The GAO Report Does (And Does Not) Establish The headline findings are modest. In its report, GAO found that neither DEA nor the Food and Drug Administration (FDA) has comprehensive written policies describing how staff should evaluate and schedule substances and that FDA has no written criteria for judging a drug’s “potential for abuse.” It also found that the memorandum of understanding (MOU) between the FDA and the National Institute on Drug Abuse (NIDA)—which describes procedures for the cooperative and timely interaction between the agencies in expediting HHS scheduling recommendations, and took effect in 1984—has not been updated in more than 40 years. Both DEA and FDA agreed to address these gaps. What GAO did not find matters far more. It reviewed 95 substances that required HHS input from 2020 through 2025. In every one, DEA requested and considered HHS’s evaluation. In all 84 cases where a final decision had been issued, DEA’s decision matched the HHS’s scientific recommendation. That is a perfect record. The report does not conclude that any scheduling decision, including on marijuana, was wrong, unlawful or contrary to the CSA. In GAO’s own words, DEA “routinely seeks and considers HHS’s scientific and medical expertise.” What The ALJ’s Order Does (And Does Not) Do On September 28, the opponents moved to add the GAO report to the record, reopen briefing and stay the case. The chief ALJ’s response was limited to pausing the proceeding while he considers the motion. That order is purely procedural. It merely halts the proceeding to permit the government, which must file, and the rescheduling opponents, who may file, to brief the motion by October 13. It casts no doubt on the substance of HHS’s evaluation or on DEA’s position at the hearing that all of cannabis belongs in schedule III. Under DEA’s rules, the ALJ’s power to receive evidence ends once the record is certified to the DEA administrator. The pause simply allows the chief ALJ to rule on the motion before that happens. It says nothing about whether the report is accurate, admissible or important. The Opponents’ Argument The rescheduling opponents’ theory runs, as follows: because DEA’s case for schedule III rests on HHS’s 2023 evaluation, DEA’s position is only as good as the process behind it. A schedule III finding requires comparing marijuana’s abuse potential to drugs in schedules I and II. They note that FDA found a high potential for abuse in 2015 but reached the opposite conclusion in 2023. Without a written standard, they say, no one can tell whether new science or a new yardstick explains the change. This argument confuses procedure with substance. No law requires the written policies GAO recommended, a point DEA made to GAO directly, stating that the CSA and its regulations set out the legal requirements. The GAO report cites no legal mandate; it simply recommended more detailed internal guidance as a good-government practice. The rescheduling record is also substantial, likely one of the most complete of any rescheduling process. It includes HHS’s 252-page detailed scientific evaluation and thousands of pages of supporting health and safety data, the attorney general’s final order and a full hearing record with the government’s opening and closing briefs thoroughly describing its position. In addition, the Justice Department’s Office of Legal Counsel (OLC) concluded in 2024 that HHS’s two-part test is a valid way to establish accepted medical use, finding that DEA’s previous five-part test was “an impermissibly narrow interpretation” of the CSA and that a substance could have a “currently accepted medical use” even without FDA approval. The OLC also concluded that schedule III, with added controls, can satisfy U.S. treaty obligations. Better Recordkeeping, Not Reversal The GAO report has value. We certainly favor government accountability and good recordkeeping. Agencies should write down how they do important work, and DEA and HHS have agreed to do that moving forward. But GAO itself described the issue modestly—not as the existential flaw the opponents claim. The report said only that the gaps “may pose a risk to the consistency” of future operations if staff leave or institutional knowledge is lost. A call for better recordkeeping is not a reason to undo sound policy. The rescheduling of marijuana rests on reams of scientific and public health and safety data, a 252-page evaluation by the scientists tasked to interpret the data and a full hearing with testimony and briefing by all parties. Nothing in GAO’s findings should disturb the schedule III recommendation. What Comes Next Yes, the stay will cost time. Briefs are due on Tuesday, and the chief ALJ may ask for supplemental briefing before ruling. After that, he will issue a recommended decision, and certification cannot occur sooner than 25 days after that recommendation is served. In our view, the likely best case for a final rule is the first quarter of 2027. Rescheduling is still moving forward. The industry should remember, however, that the surest path to federal cannabis reform without protracted litigation runs through Congress. As the GAO report itself notes, Congress can schedule substances through legislation, without the agency process that is now under attack. A statutory change in law is far less exposed to the kind of procedural challenge that opponents are mounting here. Eric P. Berlin and Joanne Caceres are partners at Dentons. The post The Marijuana Rescheduling Process Has Been Delayed—But Not Derailed (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A new federally funded study shows that “most cannabis users reported that it improved their cancer-related symptoms”—including pain, appetite, mood and insomnia—while also serving as a substitute for opioids for nearly a third of them. Researchers with the Pennsylvania State University College of Medicine, Penn State Cancer Institute and Fox Chase Cancer Center surveyed 186 patients, about a quarter of whom (26 percent) had used cannabis since their diagnosis. “A majority of users reported improvement in most cancer-related symptoms assessed, highlighting its potential role in cancer symptom management,” the study, published in the journal Supportive Care in Cancer, found. “Symptom improvement was reported for insomnia (89.7% of users), appetite (85.7%), mood (83.7%), joint pains/stiffness (83.3%), stress/anxiety/depression (81.6%), cancer-related pain (80.7%) and digestive symptoms (67.9%).” A minority of patients saw improvements in other cancer-related symptoms, including fatigue/lack of energy (49 percent), sexual interest (42 percent) and sweating/hot flashes (28 percent). The study also found that cancer patients in the sample “commonly used cannabis as an alternative to opioids for pain management,” which the researchers said “supports existing evidence suggesting that many patients prefer cannabis over opioids due to fewer side effects and better symptom control.” “30.1% reported using cannabis instead of opioids to manage pain, and 32.0% reported that cannabis helped them decrease or stop other medications.” While one aim of the research—which was funded in part by the National Institutes of Health and the National Center for Advancing Translational Sciences—was to investigate whether there would be differences in marijuana use between patients who live in urban, suburban and rural areas, it turned out that there were “broadly similar cannabis attitudes and rates of use” regardless of geography. Overall, the study found that “cannabis use was relatively common among our sample of cancer patients, who held generally favorable attitudes towards its use, with most cannabis users reporting symptom relief across a majority of cancer-related symptoms assessed.” “These findings point to the potential therapeutic benefits of cannabis among cancer populations.” Patients in the study “generally viewed cannabis as safe and beneficial,” it said, with 93 percent believing there are medical benefits and only 3 percent considering it to be unsafe. That said, 77 percent of participants voiced concerns about risks—particularly related to legal, professional and social consequences. The researchers cautioned that the study has some limitations, including its cross-sectional design and reliance on self-report data, as well as the fact that they did not differentiate cannabinoid content, dosage or route of administration of the marijuana products that patients were using. The new paper is the latest to latest to show that medical marijuana can provide relief for people struggling with cancer. For example, a recent study found that medical marijuana is “commonly” used to treat symptoms of cancer such as pain, nausea, anxiety, depression, poor appetite and sleep disturbance—and 80 percent of patients report that it provides relief and improved quality of life. A recent federally funded study found that “cannabis use conferred therapeutic benefits for several health issues commonly encountered by cancer patients“—including “pain relief, improved sleep, physical relaxation, emotional regulation, and reduction of concomitant medication.” Another recent study conducted by Minnesota state officials found that medical marijuana appears to help cancer patients by decreasing pain, nausea, vomiting, anxiety and depression while also improving sleep. A separate study found that nearly one in five cancer survivors say they’ve used CBD after getting their diagnosis—primarily to manage pain, sleep difficulties and emotional distress. And more than half of those who used it for specific symptoms reported at least some benefit. Another recent study determined that medical marijuana extracts “meaningfully” improve cancer-related symptoms such as sleep difficulties and anxiety—though responses varied among patients depending on personal preferences for individual cannabinoid content of the extracts. Researchers separately found that components of marijuana show “consistent and statistically significant anti-tumor effects” in certain types of cancer, including glioblastoma and breast cancer. The study also showed that cannabinoids seem to “enhance chemotherapy efficacy.” Another systemic review concluded that studies “consistently show” that the CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans. A similar analysis showed that CBD “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties. Scientists explored CBD’s effect on many types of cancer—including some of the most aggressive ones, such as glioblastoma, which affects the brain. They also noted it can help suppressing the growth and metastasis of other cancers, including breast, lung, colorectal, ovarian and prostate, among others. In 2025, a paper published in the journal Pharmacology & Therapeutics, assessed a range of clinical and preclinical findings that the efficacy of chemotherapy drugs can be enhanced by medical marijuana. In a sign of greater acceptance of medical applications of cannabis, President Donald Trump’s choice to serve as the next White House drug czar has called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t object to legalization, even if she might not personally agree with the policy. Also last year, a study found that “patients with cancer using cannabis report significant improvements in cancer-related symptoms.” Photo courtesy of Mike Latimer. The post Medical Marijuana Improves Cancer-Related Symptoms And Helps Reduce Use Of Opioids, Federally Funded Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

DOJ & anti-marijuana groups agree on rescheduling lawsuit calendar; Cannabis Caucus chair: review psychedelics; Poll: hikers use marijuana on trails Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW President Donald Trump complained that in Democratic-run cities it “smells of marijuana and other things worse than marijuana.” “The sidewalks are disgusting. The streets are disgusting. They’re just in bad shape… Everything’s dirty.” The Department of Justice and opponents of marijuana rescheduling have jointly agreed to a proposed briefing schedule in litigation challenging the reform—saying the U.S. Court of Appeals for the District of Columbia Circuit should “schedule oral argument as soon as reasonably practicable.” Congressional Cannabis Caucus Co-chair Rep. Brian Mast (R-FL) told Marijuana Moment that he wants the Trump administration’s cannabis rescheduling move expanded to an “across-the-board” review of the classification of psychedelics and other drugs. “I want them to review all of it… It’s not just cannabis. It’s a bigger conversation.” A new poll shows that more than a third of hikers have used marijuana to enhance their experience on the trail, while 15 percent have hiked under the influence of psilocybin. The Marijuana Policy Project is asking its supporters to send letters to Congress opposing the currently scheduled federal recriminalization of hemp THC products, saying that lawmakers should instead focus on enacting comprehensive legal regulations for all cannabis. The Rhode Island Cannabis Control Commission’s chief legal counsel said the state needs to “wait and see what the federal government does” on hemp product policy “before we can sort of act and advise our licensees in accordance with that.” Incarcerated writer Derek Jason LeCompte argues in a new op-ed that prisons should allow marijuana use, because seeing the widespread and dangerous use of the synthetic cannabinoid K2 “has made me realize it is not realistic to eradicate all illegal drug usage behind bars.” “Instead, we should find strategies for safe and responsible harm reduction, including allowing the use of organic marijuana.” / FEDERAL The Department of Justice revised a kratom-related substances scheduling proposal in a way that will allow some products to remain legally available, based on a recommendation from the Department of Health and Human Services. Rep. Jasmine Crockett’s (D-TX) political action committee endorsed a Houston, Texas ballot initiative to deprioritize marijuana enforcement. The House bill to create a pathway for patients to access Schedule I drugs got one new cosponsor for a total of 18. / STATES Connecticut’s attorney general reached a settlement with a company that allegedly illegally sold cannabis products. An Oregon senator discussed plans for legislation to restrict marijuana edibles. A South Dakota representative authored an op-ed urging Congress not to avert the federal recriminalization of hemp THC products. Colorado regulators issued an expanded health and safety advisory about marijuana products with a synthetic, unapproved flavoring ingredient. Oklahoma medical cannabis regulators are being sued for alleged sex discrimination by a former employee. Massachusetts regulators posted resources recognizing the 10-year anniversary of adult-use marijuana legalization. Montana regulators posted a review of the first year of actions by the merged Cannabis & Alcohol Regulation Division. The California Department of Fish and Wildlife assisted Nevada County police in enforcement actions against suspected illegal cannabis operations. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Boston, Massachusetts Cannabis Board will meet on Wednesday. / INTERNATIONAL Pakistani officials finalized a regulatory framework for medical and industrial cannabis. / SCIENCE & HEALTH A review concluded that “cannabinoids as promising anticancer agents and therapeutic adjuvants, predominantly in the preclinical setting.” A study found that “CBD may modulate peak cardiovascular stress and enhance sleep duration and quality, particularly REM sleep, and may promote aerobic efficiency during moderate-intensity exercise.” / ADVOCACY, OPINION & ANALYSIS The National Consumers League is urging Congress to allow the federal recriminalization of hemp THC products to take effect “unless and until a robust regulatory regime for hemp-derived products is put in place.” Eagle Forum’s president authored an op-ed calling for a “concerted effort” against “the threat posed by illegal Chinese marijuana growers across the nation.” / BUSINESS High Tide Inc. completed its acquisition of a cannabis retail store in Chestermere, Alberta, Canada. Still River Wellness workers in Torrington, Connecticut ratified a new contract. / CULTURE Former basketball player Robert Parish is urging Massachusetts voters to reject a ballot initiative to roll back the state’s marijuana legalization law. Michael Douglas and Bill Maher spoke about their past experiences selling marijuana. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Mike Latimer. The post Trump complains about cannabis smell in liberal cities (Newsletter: October 12, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

slot138.art https://slot138.art/ I really love the theme on your website, I run a web site , and i would adore to use this theme. Is it a free style, or is it custom?

Finding high-class companionship can be tough, but booking Russian Escorts in Dwarka made my weekend so special with their elegance, engaging conversation, and warm, welcoming attitude throughout our time together.

I find the growing research on psychedelics fascinating, especially when it emphasizes careful guidance, legality, and mental-health support rather than hype. Personal wellbeing also depends on simple ways to relax and reset. When I need a short break from reading or screen-heavy work, I often play Snake Game for a few minutes. Its familiar, low-pressure gameplay helps clear my mind without requiring much commitment. It’s a small habit, but surprisingly effective.

“The K2 crisis in prisons has made me realize it is not realistic to eradicate all illegal drug usage behind bars. Instead, we should find strategies for safe and responsible harm reduction.” By Derek Jason LeCompte, Prison Journalism Project This story was originally published by Prison Journalism Project. I entered my cell and found my cellmate babbling, a spaced-out look in his eyes. The pungent scent of burnt paper was overwhelming. My eyes watered. I monitored his high for about 30 minutes to make sure he did not die of an overdose or attack me because he was too intoxicated to know what was happening. Unfortunately, this is an all-too-common occurrence in New Jersey prisons. It stems from a type of synthetic cannabinoid known as K2. K2 usage has become what one state prison official called “a serious problem.” In recent months, we have received multiple memos outlining this fact from the state prison commissioner’s office, which has urged prisoners not to smoke K2, and to report people to medical personnel or guards if they appear to need help. Never in my 27 years incarcerated have I seen a substance as unregulated, widely used and dangerous as K2. No comprehensive database tracks K2 deaths in prison, but conservative estimates suggest the drug is fueling dozens of fatal overdoses across the country each year. According to the Texas Observer, K2 deaths in the Lone Star State rose from 16 in 2023 to 65 in 2024. From 2016 to 2017, Florida prisons attributed a large share of its 62 “accidental deaths” to K2 overdoses, as highlighted in the Miami Herald. And reporting from The Marshall Project found that K2 overdose deaths in Ohio rose from three in 2023 to 13 in 2024. The K2 crisis in prisons has made me realize it is not realistic to eradicate all illegal drug usage behind bars. Instead, we should find strategies for safe and responsible harm reduction, including allowing the use of organic marijuana. A legal alternative Marijuana is legal in New Jersey, and dispensaries across the state operate in a highly regulated environment. Additionally, a multitude of county jails and prisons throughout the United States offer alternatives with a similar philosophy—like “vape pens” sold at commissaries as an alternative for smokers, or Suboxone as an alternative treatment to opioids. In other countries, such as Germany, Switzerland and Spain, prisons have offered safe needle exchange programs as a way to stop the spread of disease (and the use of drugs has not increased with the implementation of those programs). A 2022 study, led by researchers at Washington State University, hints at the possible benefits of allowing marijuana use inside prisons. It found a 37 percent drop in “poisoning reports for illicit synthetic cannabinoids”—that is, K2—in states that had legalized marijuana use. As the study reported, when people have a safer option, severe medical complications can be avoided. While this is not a long-term solution to stemming drug use, states have used medical marijuana as a form of harm reduction to taper people off of opioids and ease the comedown off stimulants like methamphetamine. In the case of prisons, edible marijuana products would not violate federal anti-smoking laws nor jeopardize air quality. Right now, guards and prisoners must put up with the strong smoke and odor from K2, which people consume every day. The scent—like the smell of trash from a nearby landfill—lingers in our living quarters. A dangerous addiction A man who goes by Fastlane said it’s hard to end a K2 addiction. As soon as he’s done smoking, his body demands more. “It got my head messed up, and I can always get my hands on it,” Fastlane said. “If there was something else that wouldn’t hurt me as much, I’d use that. But there isn’t.” K2 is arguably the most popular drug inside prison because it’s much easier to smuggle inside. Unlike organic marijuana, the synthetic drug can be sprayed or laced onto paper to evade detection systems. Once it’s inside, K2 is more cost-effective and easier to keep hidden, because a small amount can be quite potent. And since the chemicals that make up the drug are constantly shifting, there’s no easy way to test people for it like there is with other drugs. Users aren’t the only ones at risk. Fastlane once nearly killed himself and his cellmate in a fire started from smoking K2. With edibles, there’s no risk of fire use. A man who goes by Mizzle, who used to struggle with substance abuse, said that edibles could help him stay away from harder drugs. “I was a pretty heavy drug user with some serious drugs,” he said. “I have to fight every day with every fiber of my being to not do drugs like K2, because it’s everywhere. If I could have some weed brownies here and there, that would help me move forward and not have the urge to use harder drugs.” Regulation would be needed Of course, there are valid reasons to not allow edibles inside prisons. It could compromise safety if many people are frequently and strongly sedated inside the prison. And harm reduction approaches like this do not address the root causes of addiction as deeply as robust substance use and mental health treatment. Prisoners could also abuse edibles and end up in “green-outs”—mental states characterized by severe paranoia, rapid heart rate, hallucinatory episodes and extreme anxiety—which would be hard for regular prison staff to manage and unsafe for everyone else, too. But these safety and use management issues already exist with K2. And prisons do not offer sufficient substance use and mental health treatment options as it is. There would need to be regulations around how much someone could have at one time and when someone could use the drug. It’s not a perfect system, but having edibles available as an alternative to a much more dangerous drug is better than doing nothing. What prison staff think I have had conversations with staff about this potential solution. No one was willing to go on the record for fear of losing their job, but the various perspectives were interesting. More than half of the nine staff members I spoke to—of varying ranks and positions—were generally in favor of it, if for different reasons. One did not want to see people in prison suffer. A couple of officers mused it would lessen their workload by curtailing overdoses and violent reactions. All of them would be happy to not have to smell the burnt paper odor. Others were more indifferent, calling edibles the “lesser of two evils.” There are staff who are unequivocally against it, though. Some are skeptical the needed regulation would be adequately applied. Others don’t condone drugs of any type at any level. And still others merely see prison as punitive —there should be no escape. But something must be done. Every other policy the department of corrections has enacted—like restricting mail, visitation and packages—has already proven to be ineffective. K2 is still abundant and remains a deadly threat. It is time to start thinking radically to save people’s lives. Derek Jason LeCompte is a writer incarcerated in New Jersey. The post It’s Time to Allow Marijuana Use in Prison (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for a very interesting blog. What else may I get that kind of info written in such a perfect approach? I’ve a undertaking that I am simply now operating on, and I have been at the look out for such info. tinyzone.org

The net will be bogged straight down together with fake sites without genuine concept nevertheless the submit has been great and also worth the particular examine. Many thanks regarding revealing this kind of with me at night. tinyzone.org

President Donald Trump has a number of complaints about cities run by Democrats—including that they smell like marijuana. During a Friday speech commemorating Columbus Day, the president criticized the “radical left” and “dirty” Democrat-run cities. “The sidewalks are disgusting. The streets are disgusting. They’re just in bad shape,” he said. “The doors going into stores are dirty. Everything’s dirty. It smells. It smells of marijuana and other things worse than marijuana.” It’s not clear what Trump meant by things that smell worse than cannabis, but he also alleged that “blue-run cities” that reek of marijuana are also “where the crime is.” Trump’s cannabis odor complaint comes as his administration is moving forward with the process of federally rescheduling marijuana. Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the attorney general signed, a hearing is considering more comprehensively moving marijuana to Schedule III. The president has a long history of comments about cannabis and has mostly praised its medical potential while often expressing concerns about broader use. Earlier this year he said that marijuana is the “best of all the alternatives” for people suffering from certain medical conditions. Trump said last year that marijuana can be a “substitute for addictive and potentially lethal opioid painkillers”—but he also said he personally is “not going to be taking it.” Last year, the president said that he has “heard great things having to do with medical, and I’ve heard bad things having to do with just about everything else.” “Medical, for pain and various things, I’ve heard some pretty good things—but for other things, I’ve heard some pretty bad things,” he said. In 2023, Trump suggested there may be a link between the use of “genetically engineered” marijuana and mass shootings. Back in 2020 Trump claimed that marijuana “does cause an IQ problem” in people who use it. Along the lines of his latest comments about problems in Democrat-run cities and the smell of cannabis, the White House said last year that Washington, D.C.’s local “failed policies opened the door to disorder” specifically citing “marijuana decriminalization.” The post Trump Complains That Democratic-Run Cities Smell Like Marijuana appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“We kind of have to wait and see what the federal government does before we can…advise our licensees.” By Christopher Shea, Rhode Island Current On less than an acre of farmland in Hopkinton, rows of hemp plants were nearing harvest. Most of their “colas”—dense clusters of buds prized for smokable flower—had already been cut ahead of a nor’easter bound for southern New England on the last weekend of September. The rest will be harvested in the next couple of weeks and turned into concentrate, destined to become products such as tinctures, 1-milligram THC gummies and 5-milligram THC lemonades, which Lovewell Farms launched earlier in September. “We’ve leaned into the cans and beverages because the state regulations allow that,” Mike Simpson, co-founder of Lovewell Farms, said in an interview standing next to the hemp plants, joint in hand. “And we’re making hand over fist doing that.” Rhode Island’s regulated hemp market generated $2.85 million in sales in 2025, according to data provided by the state’s Cannabis Control Commission. Drinks and seltzers infused with THC—the psychoactive component of the cannabis plant that can cause impairmen—accounted for $2.36 million, or about 83 percent of the total. The state had 201 licensed hemp businesses as of October. 1, including 169 retailers. But the market Simpson joined could soon be upended by a federal restriction that Rhode Island regulators say they must enforce. Starting December 11, federal law will prohibit the sale of hemp-derived cannabinoid products containing more than 0.4 milligrams of total THC per container. Existing regulations adopted by the Cannabis Control Commission in 2025 have allowed all products to contain up to 1 milligrams of total THC per serving, or 5 milligrams of total THC per package. A September 11 bulletin from the Rhode Island Cannabis Control Commission warns any product over the new limit will be considered noncompliant and subject to administrative penalties “including but not limited to monetary fines.” “Licensees are strongly encouraged to review their current inventory, assess their products against the new federal limit, and begin planning for the December 11 deadline,” the commission advised in an accompanying email. Existing regulations adopted by the Cannabis Control Commission in 2025 allow all products to contain up to 1 milligrams of total THC per serving, or 5 milligrams of total THC per package. For Simpson, the commission’s guidance raises questions about what happens to the pallets of lemonade cans stored in a dark room on the farm, ready to ship to Rhode Island liquor stores, which have been licensed to sell hemp-derived beverages for the past two years. “The idea that we would just kind of throw all that out without even engaging in a deeper conversation with the community or the industry is wild,” he said. Mariana Ormonde, chief legal counsel for the commission, said she understands the difficult position the state’s hemp licensees are in. But the state’s hands are tied when it comes to changes made at the federal level. “The reality of the situation is we can’t treat hemp like cannabis because it’s not cannabis,” Ormonde said in an interview. Lessons in chemistry Hemp became legal at the federal level after the passage of the 2018 Farm Bill, allowing products with a THC concentration of 0.3 percent or lower by dry weight. The law was meant to allow an agricultural market for hemp-based textiles, animal feeds and human wellness products centered on CBD products. But that original definition in the 2018 law did not account for ways to convert the plant to produce higher potency, paving the way for the proliferation of hemp-derived THC products like infused drinks—products which states have since scrambled to either regulate or ban. “That’s kind of what opened up Pandora’s box,” Ormonde said. Rhode Island’s hemp rules were formally adopted by the Cannabis Control Commission in 2025—just months before Congress moved to close the potency loophole created by the 2018 Farm Bill as part of legislation to reopen the federal government after last year’s shutdown. By itself, hemp produces little to no THC, the compound most commonly associated with cannabis intoxication. But that can change as the plant matures, explained Ryan Plante, Lovewell Farms’ director of cultivation. “At 30 days of a harvest, it has almost non-detectable cannabinoids in most regards,” said Plante, who studied horticulture at the University of Rhode Island. “And then afterwards, it is common for hemp to get up to 0.5 milligrams, or 0.5 percent to 1 percent of THC in that flower.” Hemp’s THC potency can also be increased by chemistry. Methods include extracting cannabinoids from the plant and converting them into compounds such as delta-8 or delta-9 THC. THC drinks derived from hemp were illegal in Rhode Island until August 2024, when the state’s former Office of Cannabis Regulation began allowing the sale of products containing low levels of delta-9 THC at licensed retailers including vape shops, liquor stores and some bars. The new federal definition was originally set to take effect November 12, but Congress pushed the effective date back one month as part of a short-term government funding bill signed by President Donald Trump in September. U.S. Sen. Jack Reed (D-R.I.) was among the 90 senators who voted for the one-month delay in August. Ben Craig, a spokesperson for Reed’s office, said Rhode Island’s senior senator supported delaying what he called a nationwide hemp ban to give lawmakers more time to develop “balanced regulations” for hemp-infused products. “He also wants to ensure responsible Rhode Island hemp businesses are not unfairly, adversely impacted by federal regulations,” Craig wrote in an email to Rhode Island Current. But Reed has also shared concerns raised by attorneys general from 39 states, including Rhode Island AG Peter Neronha, who last year sent a letter to Congress urging lawmakers to tighten the federal definition of hemp. Neronha signed onto another multistate letter in August urging Congress to reject efforts to “delay, repeal, suspend, or weaken” the federal hemp restrictions enacted last year. Simpson criticized the AG’s push for tighter restrictions, saying he has seen no evidence that hemp-derived products have increased youth access in Rhode Island. “Give me the evidence in the state of Rhode Island where we have increased youth access to cannabis,” Simpson said. “Show me the data that shows that, and then I will agree and believe you.” Timothy Rondeau, a spokesperson for Neronha’s office, said the 2025 letter sought to close a loophole in the federal definition of hemp that allowed intoxicating cannabinoid products to be sold legally. “The letter asserts that potentially harmful substances like this should be regulated, and where the regulation is patchwork across the country, federal regulation is best,” Rondeau wrote in an email to Rhode Island Current. Why is the cannabis market different? Simpson sees a double standard in the Cannabis Control Commission’s decision to enforce the federal restrictions on hemp while continuing to allow the sale of recreational cannabis, which was never legalized under federal law. “Why this, but not cannabis?” he asked. Ormonde said the difference is that the federal government has imposed a new restriction on hemp that the state cannot simply disregard. “Federal law is the supreme law of the land,” she said. She said Rhode Island can regulate cannabis under state law because the state has chosen to do so, even though cannabis remains illegal under federal law. But with hemp, she said, the state is operating within a federal framework that Congress has now changed. Keeping the hemp market would also pose challenges to the liquor retailers who have carried the drinks. Nick Fede Jr., president of the American Beverage Licensees, said the changes could make it harder for retailers to process payments for hemp products because banks would no longer allow credit card sales—as is the case with regulated cannabis sales at Rhode Island’s retail pot shops. “If it’s not federally recognized, they don’t want to touch that money,” said Fede, whose family owns Kingstown Liquor Mart in North Kingstown, which has a valid hemp retail license through March 2027. Charon Rose, spokesperson for the Cannabis Control Commission, said her understanding is that the Trump administration is considering a new framework for hemp, but that the details remain unclear. That uncertainty is one reason Ormonde said the commission is trying to avoid telling businesses to outright shut down before the federal deadline. “We kind of have to wait and see what the federal government does before we can sort of act and advise our licensees in accordance with that,” Ormonde said. In the meantime, Rose said regulators plan to revise its September 11 bulletin and issue updated guidance to licensees “in the coming days.” Still, the ongoing uncertainty has made it harder for hemp businesses like Lovewell farms to plan for next year. Simpson typically buys its 1,500 seeds from Oregon in February, ahead of the growing season. Seth Crawford, co-owner of Oregon CBD Seeds, told the Oregon Capital Chronicle he still expects to sell seeds to anyone who wants them, but anticipates demand will fall if the new federal rules reduce the market for industrial hemp processing. “It’s very hard to run a business when you want to do investments in equipment and inventory when the regulations are changing,” Simpson said. This story was first published by Rhode Island Current. The post Rhode Island Grapples With Hemp Policy As Federal Ban On THC Products Looms appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net